Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Other Events
Item8.01. Other Events
On December5, 2016, Onconova Therapeutics,Inc. (the Company)
issued a press release regarding information presented by way of
a poster and abstract at the American Society of Hematology (ASH)
Annual Meeting. Copies of the press release, poster and abstract
are attached hereto as Exhibits99.1, 99.2 and 99.3, respectively,
and are incorporated herein by reference.
Item9.01. Financial Statements and Exhibits
(d)Exhibits.
|
99.1 |
Press release issued by the Company dated December5, |
|
|
99.2 |
Poster titled: Combination of Oral Rigosertib and |
|
|
99.3 |
Abstract titled: 3167 Combination of Oral Rigosertib |
About Onconova Therapeutics, Inc. (NASDAQ:ONTX)
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib. Onconova Therapeutics, Inc. (NASDAQ:ONTX) Recent Trading Information
Onconova Therapeutics, Inc. (NASDAQ:ONTX) closed its last trading session 00.00 at 2.62 with 80,818 shares trading hands.